USPTO Patent Application: Methods for Increasing Hematopoietic Stem Cells

ChangeBridge: Patent Apps - Pharma (A61K)

Published December 15th, 2023

Detected March 26th, 2026

Summary

The USPTO has published a patent application from Imago Biosciences, Inc. detailing methods for increasing hematopoietic stem cells and treating bone marrow failure using an LSD1 inhibitor. The application was filed on December 15, 2023, and published as US20260083729A1.

View original document View source feed page

What changed

This document is a USPTO patent application (US20260083729A1) filed by Imago Biosciences, Inc. on December 15, 2023. It describes methods for increasing hematopoietic stem cells (HSCs) and treating conditions like bone marrow failure (BMF) by administering an LSD1 inhibitor. The application also covers enhancing recovery from cancer therapy and accelerating hematopoietic compartment recovery after physical insult.

As this is a patent application, it does not impose direct compliance obligations on regulated entities. However, it signals potential future developments in therapeutic approaches for blood disorders and cancer treatment recovery. Companies in the pharmaceutical and biotechnology sectors involved in HSC research or BMF therapies should be aware of this filing as it may indicate emerging intellectual property and competitive landscapes.

Source document (simplified)

← USPTO Patent Applications

METHODS FOR TREATMENT OF BONE MARROW FAILURE AND RELATED CONDITIONS

Application US20260083729A1 Kind: A1 Mar 26, 2026

Assignee

Imago Biosciences, Inc.

Inventors

Maria Kleppe, Hugh Y. Rienhoff, JR., Jennifer Dias

Abstract

Provided herein are methods for increasing the numbers of hematopoietic stem cells (HSCs) in a patient in need thereof, for treating a condition characterized by reduced numbers of hematopoietic stem cells (HSCs), such as bone marrow failure (BMF) or a BMF syndrome, in a patient in need thereof, for enhancing recovery from or improving tolerance of a near-ablative cancer therapy, and/or for reducing the damage to, or accelerating the recovery of, the hematopoietic compartment after a physical insult thereto in a patient in need thereof, comprising administering in vivo or treating cells ex vivo with an LSD1 inhibitor.